Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2000 Nov 01;1316:1081-8. doi: 10.1038/sj.bjp.0703654.
Show Gene links
Show Anatomy links
Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine.
Taglialatela M
,
Pannaccione A
,
Castaldo P
,
Giorgio G
,
Annunziato L
.
???displayArticle.abstract???
1. Ventricular arrhythmias are rare but life-threatening side effects of therapy with the second-generation H(1) receptor antagonists terfenadine and astemizole. Blockade of the K(+) channels encoded by the Human Ether-à-go-go-Related Gene 1 (HERG1) K(+) channels, which is the molecular basis of the cardiac repolarizing current I(Kr), by prolonging cardiac repolarization, has been recognized as the mechanism underlying the cardiac toxicity of these compounds. 2. In the present study, the potential blocking ability of the novel second-generation H(1) receptor antagonist mizolastine of the HERG1 K(+) channels heterologously expressed in Xenopus oocytes and in HEK 293 cells or constitutively present in SH-SY5Y human neuroblastoma cells has been examined and compared to that of astemizole. 3. Mizolastine blocked HERG1 K(+) channels expressed in Xenopus oocytes with an estimated IC(50) of 3.4 microM. Mizolastine blockade was characterized by a fast dissociation rate when compared to that of astemizole; when fitted to a monoexponential function, the time constants for drug dissociation from the K(+) channel were 72.4+/-11.9 s for 3 microM mizolastine, and 1361+/-306 s for 1 microM astemizole. 4. In human embryonic kidney 293 cells (HEK 293 cells) stably transfected with HERG1 cDNA, extracellular application of mizolastine exerted a dose-related inhibitory action on I(HERG1), with an IC(50) of 350+/-76 nM. Furthermore, mizolastine dose-dependently inhibited HERG1 K(+) channels constitutively expressed in SH-SY5Y human neuroblastoma clonal cells. 5. The results of the present study suggest that the novel second-generation H(1) receptor antagonist mizolastine, in concentrations higher than those achieved in vivo during standard therapy, is able to block in some degree both constitutively and heterologously expressed HERG1 K(+) channels, and confirm the heterogeneity of molecules belonging to this therapeutical class with respect to their HERG1-inhibitory action.
Arcangeli,
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells.
1995, Pubmed
Arcangeli,
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells.
1995,
Pubmed
Benavides,
In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent.
1995,
Pubmed
Berul,
Regulation of potassium channels by nonsedating antihistamines.
1995,
Pubmed
Bianchi,
herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells?
1998,
Pubmed
,
Xenbase
Brostoff,
Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria.
1996,
Pubmed
Chaufour,
Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist.
1999,
Pubmed
Chosidow,
Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine.
1996,
Pubmed
Craft,
Torsade de pointes after astemizole overdose.
1986,
Pubmed
Danjou,
Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects.
1992,
Pubmed
Davies,
Cardiotoxic effect with convulsions in terfenadine overdose.
1989,
Pubmed
Delauche-Cavallier,
QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine.
1999,
Pubmed
Ficker,
Molecular determinants of dofetilide block of HERG K+ channels.
1998,
Pubmed
,
Xenbase
Frech,
A novel potassium channel with delayed rectifier properties isolated from rat brain by expression cloning.
1989,
Pubmed
,
Xenbase
Frings,
Characterization of ether-à-go-go channels present in photoreceptors reveals similarity to IKx, a K+ current in rod inner segments.
1998,
Pubmed
Hamill,
Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.
1981,
Pubmed
Kiehn,
Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.
1996,
Pubmed
,
Xenbase
Leynadier,
Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group.
1996,
Pubmed
Ludwig,
Functional expression of a rat homologue of the voltage gated either á go-go potassium channel reveals differences in selectivity and activation kinetics between the Drosophila channel and its mammalian counterpart.
1994,
Pubmed
,
Xenbase
Monahan,
Torsades de pointes occurring in association with terfenadine use.
1990,
Pubmed
Pardo,
Oncogenic potential of EAG K(+) channels.
1999,
Pubmed
Patat,
Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.
1995,
Pubmed
Roy,
HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.
1996,
Pubmed
,
Xenbase
Salata,
Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine.
1995,
Pubmed
Sanguinetti,
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
1990,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Slater,
Second-generation antihistamines: a comparative review.
1999,
Pubmed
Snyders,
High affinity open channel block by dofetilide of HERG expressed in a human cell line.
1996,
Pubmed
,
Xenbase
Sorkin,
Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy.
1985,
Pubmed
Suessbrich,
Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole.
1996,
Pubmed
,
Xenbase
Taglialatela,
Patterns of internal and external tetraethylammonium block in four homologous K+ channels.
1991,
Pubmed
,
Xenbase
Taglialatela,
Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines.
1998,
Pubmed
,
Xenbase
Taglialatela,
Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications.
1998,
Pubmed
Taglialatela,
Cardiotoxic potential and CNS effects of first-generation antihistamines.
2000,
Pubmed
Trudeau,
HERG, a human inward rectifier in the voltage-gated potassium channel family.
1995,
Pubmed
Vuurman,
Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers.
1994,
Pubmed
Warmke,
A family of potassium channel genes related to eag in Drosophila and mammals.
1994,
Pubmed
Woosley,
Mechanism of the cardiotoxic actions of terfenadine.
,
Pubmed
Woosley,
Cardiac actions of antihistamines.
1996,
Pubmed
Wymore,
Tissue and species distribution of mRNA for the IKr-like K+ channel, erg.
1997,
Pubmed
,
Xenbase
Xu,
Attenuation of the slow component of delayed rectification, action potential prolongation, and triggered activity in mice expressing a dominant-negative Kv2 alpha subunit.
1999,
Pubmed
Yue,
Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization.
1996,
Pubmed
Zhou,
Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.
1998,
Pubmed
